Human immunodeficiency virus type 1 gag-protease fusion proteins are enzymatically active.

AUTOR(ES)

Kotler, M

RESUMO

We have introduced mutations into the region of the genome of human immunodeficiency virus type 1 (HIV-1) that encodes the cleavage sites between the viral protease (PR) and the adjacent upstream region of the polyprotein precursor. Segments containing these mutations were introduced into plasmids, and the retroviral proteins were expressed in Escherichia coli. The mutations prevented cleavage between the PR and the adjacent polypeptide; however, other PR cleavage sites in the polyprotein were cleaved normally, showing that the release of free PR is not a prerequisite for the appropriate processing of HIV-1 precursors.

Documentos Relacionados

• In Vitro Evolution of the Human Immunodeficiency Virus Type 1 Gag-Protease Region and Maintenance of Reverse Transcriptase Resistance following Prolonged Drug Exposure†
• Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation.
• Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments.
• Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein.
• Expression of active human immunodeficiency virus type 1 protease by noninfectious chimeric virus particles.